The ministry also said the fourth dose, or second booster, made
people over 60 twice as resistant to infection than those in the age
group who received three shots of the vaccine.
A preliminary study published by Israel's Sheba medical centre last
Monday found that the fourth shot increases antibodies to even
higher levels than the third but "probably" not to the point that it
could completely fend off the highly transmissible Omicron variant.
Israel began offering a fourth dose of the Pfizer/BioNtech vaccine
to people over 60 earlier this month as Omicron swept the country.
[to top of second column] |
The ministry said on Sunday the
study it conducted with several major Israeli
universities and the Sheba centre compared
400,000 people over 60 who received the second
booster with 600,000 people in the age group who
were given a third shot more than four months
ago.
As elsewhere, Israel has seen COVID-19 cases
spiral due to Omicron. But it has logged no
deaths from the variant.
(Reporting by Jeffrey Heller; Editing by Andrew
Cawthorne and Frances Kerry)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |